You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Tolerability of SRX246 in Huntington's Disease Patients

    SBC: Azevan Pharmaceuticals Inc            Topic: 950

    DESCRIPTIONprovided by applicantHuntington s DiseaseHDis an inherited disease that results from expansion of a trinucleotideCAGcytosine adenine guaninerepeat that encodes a polyglutamine tract in the huntingtin proteinPsychiatric symptomsincluding irritability and aggressionare common in HD patientsThese are among the most distressing aspects of the diseaseThey have adverse effects on daily life a ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTIONprovided by applicantNovel therapies for the treatment of Chikungunya virusCHIKVinfections are urgently needed to address the alarming spread of this pathogen across the AmericasWe have identified a series of potentselectiveand orally bioavailable inhibitors of CHIKV replicationIn this Direct to Phaseprojectwe will optimize this series of CHIKV inhibitors to Pre Development stage and ad ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTIONprovided by applicantMolluscum contagiosumMCis a highly contagious skin disease caused by the poxvirusMCVMC appears as lesions on the body and face and can last months years before resolvingLesions occur most frequently in childrenand immune compromised individualsThe infection is confined to skin aloneit is not systemicTransmission spreads directly from person person contactautoinocula ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Arenavirus Antiviral Lead Optimization

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Arenaviruses comprise a diverse family Several species are associated with severe arenaviral hemorrhagic fever AVHF in humans that exhibit case fatality rates as high as Human infection with arenaviruses typically occurs through contact with materials contaminated with the excretions of an infected rodent although direct human to human transmission may ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma

    SBC: PRESAGE BIOSCIENCES, INC.            Topic: 102

    DESCRIPTIONprovided by applicantImprovements in cancer diagnostics and therapeutics have positively impacted outcomes for oncology patients within select clinical nichesHoweversignificant therapeutic uncertainty awaits the majority of today s oncology patients who present in the clinic with cancer that will relapse after exhibiting an initial response or whose cancer is already refractory to stand ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced morphological analysis of cerebral blood flow for acute concussion diagnosis and return to play determination

    SBC: Neural Analytics, Inc.            Topic: 101

    Project Summary Abstract Between and million people each year suffer a mild TBI in the US alone Reliable diagnosis and prompt treatments are vital to managing the often serious short and long term sequelae resulting from mild TBI However a reliable objective and accurate method for mild TBI diagnosis outside of a hospital setting and in particular for determining RTP readiness has e ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection

    SBC: EPIPHANY BIOSCIENCES, INC.            Topic: R

    Project Summary Abstract Kaposiandapos s sarcoma herpes virusKSHVis an oncovirus that causes several cancers including Kaposiandapos s sarcomaKSIt is estimated thattoof U Sblood donors have been infected with KSHVyet in some high risk populations such as homosexual menprevalence is as high asIn spite of HAARTKS remains the second most common AIDSassociated malignancyA third of AIDS KS cases now ar ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Highly sensitive measurement of cTnI without a reader: the Xip solution

    SBC: SILICON BIODEVICES, INC.            Topic: NHLBI

    Project Summary Acute myocardial infarction (MI) is the biggest killer in the western world and is the cause of death for nearly 500,000 Americans each year. The symptoms of MI can be vague and non- specific and 7 million adults present to hospital Emergency Departments in the US each year with suspected MI. Advances in cardiac biomarkers have had a large impact on the diagnosis, risk stratificati ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. MR191_An Immunoprotectantfor Marburg Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: NIAID

    PROJECT SUMMARY Mapp BiopharmaceuticalIncMappis developing antibody based therapeutics to treat a number of infectious agentsincluding some of the most dangerous known to manthe filovirusesMarburg virus is a filovirus endemic to Africa and causes an often lethal hemorrhagic feverPresently there are no approved vaccines or therapeutics to treat Marburg virus infections and this remains a major unme ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Advancement to IND of novel BLI for pairing with cefixime

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    Project Summary Abstractlactam antibiotics are the most widely used antibiotic class in the U Saccounting for more thanof antibacterial prescriptionsAmong other rolesthey are critical therapeutics for difficult to treat infections due to gram negative pathogens such as EcoliKlebsiella pneumoniaeand Enterobacter sppHoweverthe utility of this class of antibiotics is being rapidly compromised by the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government